Angiotech to appeal UK judgment regarding UK patent
28-Feb-2006
The Angiotech European Patent remains valid and enforceable in the other designated States in Europe, in light of Angiotech's successful defense of the patent at the January 2005 European Patent Office Opposition Division decision which maintained the validity of this Patent, including claims related to stents coated with paclitaxel and a polymeric carrier. The UK decision affects only the UK version of the maintained European Patent.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.